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Correction of Dog Dystrophic Epidermolysis
Bullosa by Transplantation of Genetically Modified
Epidermal Autografts
Yannick Gache1,2,4, Didier Pin1,2,3,4, Laurent Gagnoux-Palacios1,2, Claude Carozzo3
and Guerrino Meneguzzi1,2
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin blistering condition caused by mutations in
the gene coding for collagen type VII. Genetically engineered RDEB dog keratinocytes were used to generate
autologous epidermal sheets subsequently grafted on two RDEB dogs carrying a homozygous missense
mutation in the col7a1 gene and expressing baseline amounts of the aberrant protein. Transplanted cells
regenerated a differentiated and vascularized auto-renewing epidermis progressively repopulated by dendritic
cells and melanocytes. No adverse immune reaction was detected in either dog. In dog 1, the grafted epidermis
firmly adhered to the dermis throughout the 24-month follow-up, which correlated with efficient transduction
(100%) of highly clonogenic epithelial cells and sustained transgene expression. In dog 2, less efficient (65%)
transduction of primary keratinocytes resulted in a loss of the transplanted epidermis and graft blistering
5 months after transplantation. These data provide the proof of principle for ex vivo gene therapy of RDEB
patients with missense mutations in collagen type VII by engraftment of the reconstructed epidermis, and
demonstrate that highly efficient transduction of epidermal stem cells is crucial for successful gene therapy
of inherited skin diseases in which correction of the genetic defect confers no major selective advantage in
cell culture.
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INTRODUCTION
Dystrophic epidermolysis bullosa (DEB) is a genetic disorder
characterized by extreme fragility of the skin and mucosa,
which causes unremitting blisters and erosions with unceas-
ing wound healing (Fine et al., 2008). Integument fragility
results from poor adhesion of the epidermis to the dermis,
which leaves tissues vulnerable to damage from mild friction
and trauma. In DEB, generalized blisters heal with scarring,
and extensive progressive mutilating healing results in
increasing disability and deformity of fingers and joint
contractures. The disease may also affect other areas of the
body (such as the mouth, throat, eyes, etc.) causing
discomfort and, often, difficulties in carrying out vital
activities. DEB comprises dominant and recessive (RDEB)
forms caused by mutations in the COL7A1 gene that codes
for collagen type VII (Col7), the major component of the
anchoring fibrils of the dermal–epidermal junction (DEJ).
Col7 is synthesized by epithelial basal keratinocytes and
dermal fibroblasts (Ryynanen et al., 1992; Marinkovich et al.,
1993) and enables adhesion between the epidermis and the
dermis (Christiano et al., 1993; Bruckner-Tuderman et al.,
1999). More than 500 distinct genetic mutations have been
reported in DEB, and analysis of databases indicates that the
nature of mutations and their positions correlate with severity
of the resulting phenotypes (Dang and Murrell, 2008). RDEB
patients present nonsense, frame-shift, splice-site, or missense
mutations on both COL7A1 alleles, and may thus either lack
expression of Col7, which defines the severe generalized
RDEB form, often complicated by the development of
aggressive squamous cell carcinomas and premature demise,
or express a mutated Col7, which characterizes the milder
clinical forms. Dominant dystrophic epidermolysis bullosa
patients always express abnormal Col7 molecules carrying
mutations exerting a dominant-negative effect.
No therapeutic remedy is available for DEB. Investigations
aimed at developing an efficient treatment for DEB have
proposed several approaches. Ex vivo gene therapy, which
relies on vector-based transfer of the 9.2 kb Col7 cDNA,
successfully achieved sustained expression of the recombi-
nant protein and permanent phenotypic correction of RDEB
keratinocytes and fibroblasts in vitro (Chen et al., 2002;
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Ortiz-Urda et al., 2003; Woodley et al., 2003; Gache et al.,
2004; Goto et al., 2006). Construction of transplantable skin
equivalents using genetically engineered RDEB cells demon-
strated that the expression of a transgenic Col7 restores
synthesis of functional anchoring fibrils and mechanical
resistance to trauma for at least 6 months after grafting onto
immune-deficient mice. In other studies, intradermal injec-
tion of wild-type or gene-corrected RDEB fibroblasts into
immune-deficient mice attested for polarized localization of
exogenous Col7 at the DEJ of treated animals (Ortiz-Urda
et al., 2003; Woodley et al., 2003). Accordingly, injection of
purified human recombinant Col7 into col7a1null/null RDEB
newborn mice (Remington et al., 2009) or RDEB human skin
equivalents transplanted onto mice (Woodley et al., 2004)
achieved correction of the RDEB phenotype and improve-
ment of lifespan. Significant amelioration of the phenotype
was also observed after transfer of allogeneic wild-type bone
marrow cells to col7a1null/null RDEB newborn mice (Tolar
et al., 2009) and onto RDEB patients (Petrova et al., 2010;
Wagner et al., 2010). Moreover, the availability of Col7
immune-competent hypomorphic RDEB mice, which express
low levels of wild-type protein and mimic severe RDEB, has
opened perspectives into the analysis of the molecular
pathogenesis of DEB and evaluation of innovative therapeutic
strategies, which to our knowledge is previously unreported.
Indeed, intradermal injection of wild-type fibroblasts resulted
in neo-deposition of Col7 and functional restoration of the
DEJ, which confirms that fibroblast-based treatment may be
used to transiently care RDEB (Fritsch et al., 2008). These
investigations provided evidence that the RDEB phenotype
can be cured by delivering exogenous wild-type Col7 to
RDEB immune-competent mice. However, the short lifespan
of RDEB mice represents a limitation for long-term evaluation
of therapeutic approaches.
In this context, to assess the feasibility of a long-term
curative approach of RDEB in an immune-competent back-
ground, we used a strain of Golden Retriever dogs with mild
RDEB that constitutes a unique spontaneous animal model
for the disease (Palazzi et al., 2000). These dogs carry the
homozygous missense mutation G1906S in the collagenic
domain of Col7 (Baldeschi et al., 2003) that leads to a marked
decrease in the deposition of Col7 at the DEJ, perturbs
formation of functional anchoring fibrils, and results in the
development of skin and oral mucosa blisters and erosions of
the digestive tract (Palazzi et al., 2000). These dogs offer
an opportunity to test the long-term efficacy of ex vivo
therapeutic approaches for RDEB in a large animal.
Here, we show that ex vivo gene therapy by engraftment
of the transgenic epithelia is applicable to RDEB, and that
highly efficient transduction of keratinocytes with sustained
expression of Col7 is required for successful treatment of the
condition.
RESULTS
Construction of transplantable epithelia using
gene-corrected RDEB keratinocytes
Two RDEB dogs were used for the ex vivo gene therapy trial.
Primary keratinocytes obtained from skin biopsies of dog 1
(D1) and dog 2 (D2) were transduced using high-titer
suspensions of a retroviral vector expressing the wild type
(WT) dog Col7 cDNA under the control of the mouse stem
cell virus long-terminal repeat (Baldeschi et al., 2003).
Expression of the transferred cDNA was first monitored by
immunofluorescence using mAb LH7.2 to Col7. In trans-
duced cultures, 490% of dog D1 (r-D1) and D2 (r-D1)
keratinocytes were reactive to the antibody as estimated by
image analysis of randomly chosen fields of growing cell
cultures (Figure 1a). Expression and secretion of recombinant
WT 320-kDa Col7 was further confirmed by western blot
analysis of spent cell culture medium (Figure 1b). Integration
of the Col7 transgene in the transduced keratinocyte genome
was confirmed by PCR amplification of genomic DNA
extracted from infected cells (Figure 1c). Reverse transcrip-
tase-PCR analysis of mRNA extracted from r-D1 and r-D2
cells, and direct nucleotide sequencing of amplified cDNA,
showed expression of recombinant WT Col7 (Figure 1d).
Clonogenic efficiency of transduced RDEB keratinocytes was
then evaluated by colony-forming efficiency assays (Murauer
et al., 2011). RDEB keratinocytes before (D1 and D2) and
after transduction (r-D1 and r-D2) displayed a comparable
colony-forming efficiency, in the range of 36–32% for D1 and
r-D1, and 30–24% for D2 and r-D2, which suggested that
infection and expression of recombinant Col7 preserved the
cell clonogenic potential (Figure 1e). However, the number
of abortive cell colonies was higher in D2 (16–22%) than in
D1 (8–10%) (not shown). To evaluate the transduction
efficiency of r-D1 and r-D2 keratinocytes, cells were seeded
at low density. Cell colonies were randomly isolated,
expanded, and then analyzed to detect integrated Col7
transgene cDNA. PCR amplification of genomic DNA, using
primers specific for WT Col7, revealed that all (11/11) of the
r-D1 clones and 65% (7/11) of the r-D2 clones carried
integrated copies of the transgene (Figure 1f). Expression of
the WT Col7 was then confirmed by reverse transcriptase-
PCR amplification of total mRNA isolated from each clone
and nucleotide sequencing of the cDNA amplicons (not
shown), which revealed efficient transduction of D1 kerati-
nocytes and, for D2, a reduced content of in vitro efficiently
growing colonies targeted by the vector.
Gene-corrected and control keratinocytes were used to
construct epithelial sheets. Histochemical analysis showed
that the stratified epithelia were formed by 4–6 cell layers of
differentiating keratinocytes, with keratohyalin granules
within the suprabasal cell layers (Figure 2, HE). Both
suprabasal and basal keratinocytes were reactive to mAb
KL1 specific to suprabasal keratins (Figure 2, KL1) (Ansai
et al., 1993). Such an unusual expression pattern, currently
observed in skin equivalents made in vitro and during skin
wound healing in vivo, is believed to reflect the hyperpro-
liferation of basal keratinocytes (Demarchez et al., 1986). In
our artificial epithelia, this idea was confirmed by detection
of numerous Ki67-positive basal cells. Expression of the
recombinant Col7 was monitored in frozen sections of the
artificial epidermis by immunofluorescence staining using
mAb LH7.2, which yielded a strong polarized intracellular
labeling of basal and suprabasal keratinocytes in the
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transgenic epithelia compared with controls (Figure 2,
bottom panels). Ectopic presence of recombinant gene
products in suprabasal layers is currently observed in vitro
in the transplantable epithelia when transgene expression is
driven by strong retroviral promoters. However, tissue
homeostasis is not affected (Gache et al., 2004; Rico et al.,
2005; Mavilio et al., 2006).
Transplantation and follow-up of the gene-corrected epithelia
For grafting experiments, two partial-thickness skin excisions
were symmetrically performed on the posterior back of each
dog using a dermatome. Autologous genetically modified and
control epithelial sheets (10 6 cm2) were transplanted on
each side of the dogs’ backs. Graft take was assessed 11 days
later. All grafted areas presented irreversible absence of hair,
which made the transplanted tissue easily distinguishable
during the follow-up period and 30% contraction (not
shown). Punch biopsies of 6mm were collected at 1, 2, 5,
and 12 months after grafting. In both dogs, at 1 month,
transplanted epidermal sheets generated a thick, well-
organized tissue with 11–14 layers of differentiating epider-
mal cells sitting on a monolayer of polarized basal
keratinocytes that lined a dermis densely populated by
fibroblasts (Figure 3a). Between 2 and 5 months, the thickness
of the epidermis gradually reduced to finally display the
typical pattern of a dog skin with 4–5 keratinocyte layers and
a dermis containing sparse fibroblasts. Interestingly, during
the first 2 months, the transgenic skin implants of the two
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Figure 1. Recombinant Col7 expression in transduced keratinocytes. (a) Immunofluorescence staining: mAb LH7.2 to Col7 strongly reacts to transduced cells.
(b) Immunoblots of the culture media detect a strong immunoreactive 320-kDa dog Col7 band in transduced keratinocytes and a fainter corresponding band in
parental D1 and D2 cells. A lower unspecific 124-kDa band is also visible. (c) PCR analysis of genomic DNA using primers specific to WT Col7 detects a 635-bp
cDNA fragment in reverted cells. (d) RT-PCR and sequencing of total mRNA detect expression of WT (GGC) and mutated (AGC) mRNA in the reverted
keratinocytes. (e) RDEB keratinocytes display a comparable colony-forming ability in culture before (D1 and D2) and after (r-D1 and r-D2) transduction. (f) PCR
analysis of genomic DNA purified from highly proliferating clones detects the WT 635-bp Col7 cDNA fragment in 100% of r-D1 and 65% of r-D2 keratinocytes.
Col7, collagen type VII; RDEB, recessive dystrophic epidermolysis bullosa; RT-PCR, reverse transcriptase-PCR; WT, wild type.
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dogs were macroscopically and histologically indistinguish-
able from each other, and resisted to mechanical stress.
However, at month 5, the D2 skin specimen revealed the
presence of a cleavage at the DEJ with blisters similar to those
detected in grafted control epithelia harboring the empty
vector. On the contrary, the transgenic D1 skin implant
showed the absence of dermal–epidermal separation through-
out the follow-up. Subsequent immunohistological analysis
showed that 2 months after transplantation, the transgenic
epidermis contained proliferating Ki67-positive basal kerati-
nocytes and that the major basement membrane adhesion
components, including laminin 332, displayed the expected
focalized expression (Figure 3b). In suprabasal layers,
keratinocyte differentiation markers, including suprabasal
keratins and involucrin, were actively expressed. A few
melanocytes and Langerhans cells were also detected in the
basal and first suprabasal layers, whereas endothelial cells
indicative of formation of blood capillary vessels were found
to be evenly distributed in the underlying dermis (Figure 3b).
These observations suggested successful take of the grafted
tissue in terms of formation of a structured basement
membrane, tissue differentiation, self-renewal capacity,
stimulation of dermis vascularization, and colonization by
antigen-presenting cells.
Permanent expression at the therapeutic level of the
exogenous collagen VII
To verify whether the discrepant results observed with r-D1
and r-D2 skin implants correlated with different expression
rates of the Col7 transgene, frozen sections of gene-corrected
and control skin grafts were analyzed by immunostaining
(Figure 4a). In r-D1 graft, deposition of Col7 appeared to be
enhanced all along the basement membrane throughout the
follow-up (Figure 4a, top). Suprabasal keratinocytes were also
immune-reactive, which reflected ectopic expression of
recombinant Col7 due to active expression of the transgene.
These results strikingly contrasted with observations made on
control engraftments made with keratinocytes expressing the
empty vector (Figure 4a, right panels) and the original
integument of the dog (not shown) that presented faint Col7
labeling localized at the blister roofs. In r-D2 graft,
immunofluorescence attested to a high deposition of Col7
up to 5 months after implantation (Figure 4a, bottom).
However, ectopic expression of the transgene in the
epidermis suprabasal layers was much fainter than in r-D1
graft, and was only detected at month 1 after grafting,
which suggested a loss of transplanted keratinocytes and
accumulation of mutated Col7 unable to stabilize the DEJ
(Figure 4a, left panels). To corroborate this possibility,
genomic DNA was extracted from biopsies obtained
from the grafted epithelia and used for PCR amplification
of a 635-bp fragment of the Col7 DNA carrying nucleotide
5716, which is mutated in RDEB dogs. In parallel, and
using the same procedure, total mRNA was isolated from
biopsies to amplify and identify transcripts specific to the WT
collagen transgene. The transgene was detected in r-D1
throughout the 12 months follow-up, whereas it was only
detected 1 month after grafting in r-D2 (Figure 4b). Similar
results were obtained in experiments for expression analysis
(Figure 4c). Taken together, these data show that long-term
restoration of epidermal adhesion in the r-D1 grafted
epithelium correlates with the presence of genetically
modified keratinocytes that synthesize the transgenic Col7,
whereas the development of blisters in the r-D2 integument
correlates with declining expression of transgenic Col7
consequent to the loss of gene-corrected keratinocytes.
Moreover, no shedding of recombinant virus could be
detected either in the dermis or in the serum of the
transplanted dog (not shown).
In the skin, long-term expression of a transgene relies on
the presence of genetically engineered epidermal stem cells
which are identified by their high clonogenic potential
HE KL1 Ki67
LH7.2LH7.2
r-D1 r-D2
LH7.2
D1/D2
20 µm
Figure 2. Analysis of transplantable epithelial sheets before grafting onto RDEB dogs. H&E staining visualizes the stratified epithelia composed of 4–5
keratinocyte layers. Immunohistochemistry using mAb KL1 detects epidermal keratins in all layers of the reconstructed epidermal sheets; mAb Ki67 detects the
presence of numerous proliferating cells in the basal cell layer, and mAb LH7.2 to Col7 (green) is strongly reactive to basal and suprabasal cells in the reverted
r-D1 and r-D2 epithelia, and to basal cells in the D1 and D2 (not shown) non-reverted epithelia. Nuclei stained with DAPI (blue). Bar¼20 mm. DAPI, 40,6-
diamidino-2-phenylindolel; H&E, hematoxylin–eosin; RDEB, recessive dystrophic epidermolysis bullosa.
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(Larcher et al., 2007). To evaluate the content in clonogenic
genetically modified keratinocytes of the r-D1 epidermis,
primary keratinocytes were isolated from a biopsy 5 months
after grafting, expanded in vitro, and plated at low density
onto lethally irradiated 3T3-J2 fibroblasts. Cell cultures were
either stained 12 days after plating using rhodamine B to
score the cell colonies or used to isolate individual colonies
further expanded for transgene integration and expression
analysis (Figure 4d and e). Clonal analysis revealed that cell
cultures derived from the r-D1 graft contained 22% of
clonogenic cells in average and that 100% of the isolated
clones carried the Col7 transgene (Figure 4d and e) and
expressed WT mRNA (not shown). Conversely, in r-D2 graft,
clonal analysis failed to detect any genetically modified cells
(not shown), suggesting the absence of clonogenic cells
among transduced r-D2 keratinocytes.
Although no clinical signs of graft rejection, including
inflammation, were observed during the follow-up, a possible
occurrence of immune reaction raised against the wild-type
recombinant Col7 was investigated by monitoring the
presence of cellular infiltrates in the grafted skin. Two
months after transplantation, immunohistochemistry of trans-
genic tissues showed that the number of CD4þ , CD8þ T
lymphocytes, CD68þ macrophages, and CD79aþ B lym-
phocytes were comparable with that observed in control
implants (Supplementary Figure S1a and b online) and in the
non-involved skin (not shown). Possible induction of a Col7-
specific immune response was also investigated by western
blot analysis of cell culture media spent by transgenic dog
keratinocytes using sera collected from the two dogs
(Supplementary Figure S1c online), which failed to react
against the Col7 protein. On the contrary, Col7 was detected
by pAb NC2-10 specific to Col7, and by a serum of a patient
with epidermolysis bullosa acquisita (Woodley et al., 1988),
suggesting that, at the time of analysis, no immune reaction
was induced by the grafts.
Lam 332
KL1
Bla36 FVIII
Ki67
Involucrin
D1 D2
CT
L 
gr
a
fts
R
ev
 g
ra
fts
1 
M
on
th
1 
M
on
th
2 
M
on
th
s
5 
M
on
th
s
12
 M
on
th
s
Figure 3. Histopathology of the reconstructed epithelia after transplantation. (a) H&E staining of control (CTL) and reverted (Rev) grafts. At month 1,
a differentiated epidermis is generated that adheres to the underlying dermis. The dermal–epidermal junction appears intact for the entire follow-up in D1,
but blistered at month 5 in D2 and at month 1 in CTL grafts. Bar¼ 20 mm. (b) Immunostaining at month 2: laminin 332 (red) displays a linear staining of the
basement membrane. DAPI (blue) stains nuclei. Involucrin (green) is expressed in the upper spinous layers. Nuclei stained with DAPI (red). KL1 mAb stains
suprabasal cells. mAb Ki67 and mAb Bla 36 identify proliferating keratinocytes and dendritic cells, respectively. pAb anti-FVIII detects neovessels in the
underlying dermis. Bar¼50 mm. DAPI, 40,6-diamidino-2-phenylindolel; H&E, hematoxylin–eosin.
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DISCUSSION
Using a spontaneous dog model of RDEB and a viral
vector expressing a wild-type dog Col7, we demon-
strate the feasibility of ex vivo gene therapy of RDEB
based on grafting of genetically corrected autologous
epithelia.
In the first step of our procedure, dog RDEB epidermal
cells were efficiently transduced, which allowed synthesis
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Figure 4. R-Col7 in the regenerated epidermis. (a) Immunofluorescence analysis of Col7 in reverted (r-D1, r-D2) and control (D1, D2) epithelia: besides the
DEJ, mAb LH7.2 stains the cytoplasm of suprabasal cells until month 2 in r-D2 and throughout follow-up in r-D1. Blister roofs (asterisks) in controls. Nuclei
(blue). Bar¼50 mm. (b) r-Col7 gDNA and (c) mRNA are detected in grafted skin biopsies throughout follow-up in r-D1, but only at month 1 in r-D2. (d) Clonogenic
cells account for 22% of total r-D1 cell population derived from a graft biopsy. (e) PCR analysis of genomic DNA extracted from isolated r-D1 cell colonies
demonstrates that 100% of the clones contain the transgene. Col7, collagen type VII; DEJ, dermal–epidermal junction. The color reproduction of the figure is available
at the Journal of Investigative Dermatology journal online.
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and secretion of elevated amounts of recombinant Col7.
In RDEB dog 1, the grafted genetically modified epithelia
permanently persisted during the 2 years follow-up period,
underwent physiological renewals, and preserved a stable
expression of the curative protein. This resulted in a firm
cohesion of the epidermal compartments and resistance to
mechanical stress, notably to manual pinching. Detection
of persistent immunoreactive Col7 within suprabasal kerati-
nocytes and the high ratio of transduced clonogenic
keratinocytes isolated from the grafted area 5 months after
grafting attested to the efficient targeting of epidermal stem
cells, thus ensuring permanent auto-renewal of the grafted
tissue. On the contrary, abortive cell colonies were scored
during in vitro expansion of primary keratinocyte cell cultures
obtained from RDEB dog 2 (Figure 1e), which denoted
underrepresentation of epidermal stem cells in the biopsied
areas of the integument. Therefore, transduction efficiency
was insufficient to target enough highly clonogenic epithelial
cells able to generate permanently therapeutic grafts (Mathor
et al., 1996). This accounts for the decline of the transduced
cell population within the graft, attested by a progressive
attenuation of suprabasal reactivity to anti-Col7 antibodies
and loss of recombinant Col7 mRNA 2 months after
transplantation. As shown in JEB (Mavilio et al., 2006),
unremitted healing of the involved epidermolysis bullosa skin
tends to deplete the patients’ pools of epidermal stem cells,
which constitutes a major draw back, because insufficient
stem cell regeneration results in the loss of grafted tissues.
Our observations imply that restoration of functional Col7
fails to endow transduced RDEB keratinocytes with a
selective advantage in vitro. This contrasts with the efficient
restoration of cell adhesion and clonogenic potential
observed in junctional epidermolysis bullosa keratinocytes
transduced with a curative cDNA, in which recovery of a
functional laminin 322 confers a remarkable selective
advantage and outgrowth over the untransduced counterparts
(Dellambra et al., 1998; Vailly et al., 1998), which facilitates
take and persistence of the grafted epithelia (Spirito et al.,
2006). Thus, in RDEB keratinocytes, transduction efficiency is
the crucial parameter for generation of transplantable tissues.
The 3-month delay between complete loss of recombinant
Col7 expression and blister formation in transgenic D2
implants reflects the beneficial effects provided by functional
Col7. Indeed, intradermal injection of either purified wild-
type Col7 or gene-corrected RDEB fibroblasts into mice
sustains incorporation of Col7 into the basement membrane
for several weeks and prevents skin blistering, which provides
for development of novel treatment strategies based on
protein and cell therapy, (Ortiz-Urda et al., 2003; Woodley
et al., 2003; Fritsch et al., 2008). However, because of the
half-life of Col7, which is relatively short compared with that
of other collagens (Kern et al., 2009), and the rapid
senescence of WT fibroblasts both in vitro and in vivo
(Krueger, 2000; Petrova et al., 2010), RDEB protein and cell
therapy requires frequent rounds of local injections, which
makes permanent treatments by ex vivo gene transfer an
interesting option. Indeed, grafting of large areas of the skin,
each associated with flexion contractures and absence
of hairs, may be required, although more limited surfaces
could be treated, such as feet and hands in connection
with degloving procedures (Bernardis and Box, 2010).
Combination of ex vivo gene therapy and local periodic
treatments of the skin and mucosa may also be envisaged,
which could provide a valid approach complementary to
the encouraging curative approaches of RDEB based on
allogeneic embryonic bone marrow transplantation (Wagner
et al., 2010).
The successful engraftment of RDEB dog 1 demonstrates
that transplantation of the epithelia made with reverted
autologous keratinocytes may be a valid therapeutic option
for human RDEB patients. Owing to the density of hair
follicles and elasticity of canine skin, the grafting technique
used for our clinical protocol demanded partial excision
of the dermis with removal of hair bulbs from the recipient
bed, which implies ablation of the sebaceous glands and
sweat glands. Such an invasive procedure is not required in
human patients, in whom a laser de-epithelialization of the
area to be grafted is sufficient to adequately receive
genetically modified keratinocytes (Jiang et al., 2002; Mavilio
et al., 2006), which circumvents any risk of contraction
caused by ablation of the superficial dermis. Interestingly,
the genetically modified grafts displayed a normal clinical
aspect already 1 month after transplantation, with a
stratified epidermis undergoing a canonical keratinization
process, and colonization by melanocytes, endothelial, and
dendritic cells. As previously determined in transgenic mice
and humans (Larcher et al., 2001; Rico et al., 2005; Mavilio
et al., 2006), ectopic overexpression of the transgene
in suprabasal keratinocytes did not interfere with
epidermal homeostasis. However, in a clinical situation,
a tissue-specific and regulated expression of the transgene
is required, which provides a compelling reason for the
search of adapted human promoters driving sustained and
focalized physiological expression (Titeux et al., 2010;
Murauer et al., 2011).
Interestingly, BLA 36þ cells, which are known to contain
early and activated B lymphocytes in humans (Imam et al.,
1990) and also dendritic cells in the dog skin were identified
(DP unpublished results). As dendritic cells were undetect-
able in the original keratinocyte cultures and reconstructed
skin equivalents, dendritic cells observed in the grafted
epidermis presumably colonized from the host surrounding
tissues. Considering the tropism of Langerhans cell for the
epidermis, such an early colonization may be of clinical
relevance, because Langerhans cells in the novel epidermis,
could recover a role in specific immunity, possibly as
immunoregulatory cells (Strid et al., 2008; Lutz et al., 2010;
Stoitzner et al., 2010). Neo-antigens synthesized by kerati-
nocytes expressing a transgenic DNA and grafted on
immune-competent mice raise a vigorous local immune
response and clearance of transgenic cells. These changes are
associated with a dense CD4þ and CD8þ cell infiltration
within the graft bed and high titers of collagen VII-specific
IgG in the serum (Ghazizadeh et al., 2003; Lu and
Ghazizadeh, 2005). Although transient infiltration of T cells
between two time points of the follow-up cannot be formally
www.jidonline.org 2075
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excluded, no recruitment of infiltrating lymphocytes or
macrophages was detected in the two dogs, which makes
unlikely a cell immune reaction in dog 2. Indeed, similar to
the JEB patient treated in a successful pilot clinical trial
(Mavilio et al., 2006), RDEB dogs express low levels of the
mutated protein and therefore the wild-type transgene
product is apparently not recognized as a neo-antigen. These
studies do not allow conclusions on the immune responses in
patients who lack the involved protein and are affected by the
most severe forms of the condition. In fact, the risk of immune
response is lower in patients suffering from moderately severe
RDEB associated with residual Col7 expression, which
permits the development of an immune tolerance toward
the protein and avoidance of early immunosuppressive
treatments (Pendaries et al., 2010). To this respect, immuno-
logical tests useful for selecting RDEB patients for inclusion in
clinical trials and monitoring the possible immune
response to Col7 after treatment have been devised
(Pendaries et al., 2010). The results of such tests are to be
combined with an evaluation of the risk of antigenicity of the
curative protein with regard to the genetic mutation(s) of
potential candidates.
To our knowledge, the permanent therapeutic effect of a
recombinant WT Col7 delivered in vivo by genetically
engineered RDEB skin grafted onto an autologous large and
immunocompetent animal has not been previously reported.
During the clinical follow-up, and subsequent observations,
which exceeded a 2-year period for the successfully treated
dog 1, the genetically engineered graft displayed the clinical
and physiological properties of a normal hairless skin
sustaining expression of functional Col7, which provides
the dermal–epidermal adherence. No undesired genotoxic
effect was ever detected despite the use of a classical
oncoretroviral vector. Therefore, our results demonstrate the
feasibility of an ex vivo gene therapy approach for the
specific situation of those RDEB patients harboring disabling
genetic mutations which, on one side permits residual
expression of an aberrant Col7, whereas on the other,
reduces the risk of rejection of the curative molecule. Our
results also push toward the construction of novel securized
viral vectors, (Titeux et al., 2010), and the development of
alternative technologies of gene transfer (Mates et al., 2009;
Staunstrup et al., 2009; Wilson and George, 2010), which, by
increasing the safety and efficacy of autologous transplanta-
tion of genetically corrected skin, can replace the vectors
used in this study, which, so far, are ineligible for clinical
trials in humans.
MATERIALS AND METHODS
RDEB dogs
In RDEB Golden Retrievers, the homozygous genetic mutation
5716G-to-A, which substitutes a Gly to a Ser (G1906S) results in
reduced secretion of abnormal Col7 and assembly of anomalous
anchoring fibrils abutting the lamina densa (Palazzi et al., 2000;
Baldeschi et al., 2003). Clinically, the dogs present the hallmarks of
RDEB with severe ulcerations and hemorrhagic blisters of the
integuments and mucosa. By breeding a homozygous RDEB dog
with a heterozygous healthy carrier bitch, five RDEB newborns were
identified by clinical examination and genotyping for inheritance
of the G1906S mutation. Compared with unaffected pups, young
RDEB dogs had equivalent sizes, but were significantly thinner.
Diet optimization improved their weight at adulthood (26–27 vs
31–33 kg for unaffected dogs). One dog died at 1 year of age, a
second one developed an ichthyosis together with RDEB, and a
third suffered from chronic ulcerated and infected lesions on the
back. The two remaining RDEB dogs were included in the trial and
kept in a dedicated housing space during and after the study.
Research was conducted according to the principles outlined in the
Guide for Laboratory Animal Facilities and Care. Protocols and
facilities were approved by the Animal Care and Use Committee of
the Veterinary School of Lyon (Protocol no: 03/28, authorized:
1 June 2004).
Retroviral vector, cell cultures, and gene transfer
The mouse stem cell virus -Col7 retroviral vector encoding the 9-kb
full-length dog Col7, the packaging procedures in 293T cells, and
pseudotyping with the VSV-G envelope glycoprotein were as
reported previously (Baldeschi et al., 2003). Titers (4.4 107
c.f.u.ml1) were determined by real-time quantitative PCR (Towers
et al., 1999). Primary dog keratinocytes obtained from skin biopsies
were grown on feeder layers of lethally irradiated mouse 3T3-J2
fibroblasts in DMEM:Ham’s F12 (3:1) medium (Hyclone, Perbio
Sciences, Bezons, France) (Rheinwald and Green, 1975). Colony-
forming efficiency assays were performed as reported previously
(Murauer et al., 2011). Cell cultures were transduced at multiplicity
of infection 20. To assess the transduction efficiency of potentially
highly clonogenic epithelial cells, infected cell cultures were
trypsinized, counted, and plated (500 cells in 100-mm Petri dishes)
on 3T3-J2 feeder layers. After 9 days in culture, clones were
trypsinized and individually amplified.
Generation of epidermal sheets and surgical procedures
To prepare transplantable epithelia, sub-confluent keratinocyte cell
cultures were trypsinized and cells (6 103 cells per cm2) were
seeded on J2 feeders in 150-cm2 flasks. Cells were maintained in
culture for 3 days after confluence to obtain cohesive epidermal
sheets, which were detached from the flasks by dispase treatment
and grafted on the dog’s back as detailed in Supplementary
Information online. Punch biopsies (0.6 cm) were collected 1, 2, 5,
and 12 months after transplantation. Clinical follow-up exceeded
one additional year.
Immunohistochemistry and western blot analysis
Skin biopsies were either embedded in paraffin blocks or snap frozen
in liquid nitrogen in the optimal cutting temperature medium.
Hematoxylin–eosin and immunostaining of paraffin sections, and
indirect immunofluorescence analysis of frozen sections, were
performed as described previously (Gache et al., 1996; Del Rio
et al., 2002). Preparations were examined under a Zeiss Axiophot
microscope (Carl Zeiss SAS, LePecq, France). Antibodies used for
immunostaining are listed in Supplementary Information online.
Recombinant Col7 was purified from serum-free media of trans-
duced RDEB keratinocytes (Gache et al., 2004). Samples were
subjected to 6% SDS-PAGE, blotted onto nitrocellulose filters, and
reacted with anti-Col7 pAb NC2-10 (Bruckner-Tuderman et al.,
1995). To detect circulating anti-Col7 Ab, blots were reacted with
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either undiluted D1 and D2 sera or serum from a human patient with
epidermolysis bullosa acquisita.
DNA and RNA analysis
Genomic DNA was isolated from cell cultures and from punch
biopsies of grafted skin using the DNeasy Tissue Kit (Qiagen, Hilden,
Germany) and analyzed by PCR amplification. Genomic DNA
samples (0.2 mg) were amplified using primers P1: 50-GGAGA
GAAGGGTGACCGAGG-30 and P2: 50-ACGGCGTCGTTCTGG
CATG-30, which amplified a 635-bp fragment of Col7 cDNA
(nucleotides 5287-5922; Genbank accession no. AY183408) and a
3.5 kb fragment from the endogenous Col7 gene. The amplification
products were analyzed by 1% agarose gel electrophoresis. Total
RNA was extracted from cultures of transduced and control keratino-
cytes, and from frozen skin biopsies using RNAqueous-4PCR kit
(Ambion, Austin, TX). Total mRNA was reverse-transcribed in 20-ml
volumes as recommended (Promega, Madison, WI). The reaction
products were used for PCR amplification of the Col7 cDNA using
primers P1 and P2 amplifying the 635-bp fragment overlapping mutation
G1906S. PCR products were sequenced using an ABI Prism 310
automated sequencing system (Applied Biosystems, Foster City, CA).
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